Nav: Home

Immunotherapy combo achieves reservoir shrinkage in HIV model

March 16, 2020

Stimulating immune cells with two cancer immunotherapies together can shrink the size of the viral "reservoir" in SIV-infected non-human primates treated with antiviral drugs, researchers have concluded. The reservoir includes immune cells that harbor virus despite potent antiviral drug treatment.

The findings, reported in Nature Medicine, have important implications for the quest to cure HIV, because reservoir shrinkage has not been achieved consistently before. However, the combination treatment does not prevent or delay viral rebound once antiviral drugs are stopped - illustrating how difficult achieving a cure will be. Monkeys infected with SIV (simian immunodeficiency virus) are considered to be the best model for HIV infection in animals.

"It's a glass-half-full situation," says senior author Mirko Paiardini, PhD. "We concluded that immune checkpoint blockade, even a very effective combination, is unlikely to achieve viral remission as a standalone treatment during antiretroviral therapy."

He adds that the approach may have greater potential if combined with other immune-stimulating agents. Or it could be deployed at a different point -- when the immune system is engaged in fighting the virus, creating a target-rich environment. Other HIV/AIDS researchers have started to test those tactics, he says.

Paiardini is an associate professor of pathology and laboratory medicine at Emory University School of Medicine and a researcher at Yerkes National Primate Research Center. The study was performed in collaboration with co-authors Shari Gordon and David Favre at the University of North Carolina at Chapel Hill and GlaxoSmithKline; Katharine Bar at the University of Pennsylvania; and Jake Estes at Oregon Health & Science University.

"This was a very complex study and we are especially thankful to veterinarians and animal care staff," Paiardini adds.

Although antiviral drugs are available that can suppress HIV to the point of being undetectable in blood, the virus embeds itself in the DNA of immune cells, frustrating efforts to root it out. Only two individuals have ever achieved what their doctors consider a durable cure, and they went through a bone-marrow transplant for leukemia or lymphoma -- not widely applicable.

Paiardini and his colleagues reasoned that chronic viral infection and cancer produce similar states of "exhaustion": immune cells (T cells) that could fight virus or cancer are present, but unable to respond. In long-term HIV or SIV infection, T cells harboring the virus display receptors that make them targets for checkpoint inhibitors, cancer immunotherapy drugs that are designed to counteract the exhausted state. In the context of HIV infection, these types of drugs have been tested to a limited extent in people living with HIV who were being treated for cancer.

In the Nature Medicine paper, the researchers used monkey biosimilar versions of ipilimumab and nivolumab, which block the inhibitory receptors CTLA-4 and PD-1, respectively. In monkeys that received both CTLA-4- and PD-1-blocking agents, researchers observed a stronger activation of T cells, compared to only PD-1 blockade. DNA sequencing of viruses in the blood revealed that a broader range of viruses were reactivated with the combination, compared to single checkpoint inhibitors.

"We observed that combining CTLA-4- and PD-1 blockade was effective in reactivating the virus from latency and making it visible to the immune system," Paiardini says.

In previous studies, limited shrinkage of the viral reservoir has been seen only inconsistently with single checkpoint inhibitors or other immune-stimulating agents. Only combination-treated animals showed a consistently measurable and significant reduction in the size of the viral reservoir. This was measured with "DNAscope", an imaging technique to visualize infected cells within tissues, and by measuring the frequency of CD4 T cells, the main targets of HIV and SIV, harboring intact viral DNA.

Despite this effect, once antiviral drugs were stopped, the virus still came back to the same level in combination-treated animals.

"We believe this is due to having much less viral antigens around after long-term antiretroviral therapy, compared with the situation in cancer," says Justin Harper, lab manager and first author of the paper. "This makes much more difficult for the immune system to recognize and kill those cells."

A note of caution: the equivalent combination of CTLA-4 and PD-1 blockade in humans has been tested in the context of cancer treatment. While the two drug types can be more effective together, patients sometimes experience adverse side effects: severe inflammation, kidney damage, or liver damage.

In the Nature Medicine paper, the combination-treated animals did not experience comparable adverse events, the researchers reported. Further investigation is necessary to determine whether the combination of checkpoint inhibitors exhibits an acceptable toxicity profile in people living with HIV without cancer.
-end-
This research was supported by Emory's Center for AIDS Research and Consortium for Innovative AIDS Research in Nonhuman Primates, the National Institute of Allergy and Infectious Diseases (R01AI116379, R21/R33AI116171, UM1AI124436, UM1AI126619 <- subcontract to GlaxoSmithKline and Qura Therapeutics, P30AI050409), the NIH director's Office of Research Infrastructure Programs (Primate centers: P51OD011132, P51OD011092), and the National Cancer Institute (contract HHSN261200800001E).

Emory Health Sciences

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.